
Day One Biopharmaceuticals, Inc. – NASDAQ:DAWN
Day One Biopharmaceuticals stock price today
Day One Biopharmaceuticals stock price monthly change
Day One Biopharmaceuticals stock price quarterly change
Day One Biopharmaceuticals stock price yearly change
Day One Biopharmaceuticals key metrics
Market Cap | 1.27B |
Enterprise value | 750.25M |
P/E | -5.99 |
EV/Sales | N/A |
EV/EBITDA | -5.48 |
Price/Sales | N/A |
Price/Book | 2.51 |
PEG ratio | -0.11 |
EPS | -2.48 |
Revenue | N/A |
EBITDA | -235.09M |
Income | -208.93M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeDay One Biopharmaceuticals stock price history
Day One Biopharmaceuticals stock forecast
Day One Biopharmaceuticals financial statements
Jun 2023 | 0 | -45.86M | |
---|---|---|---|
Sep 2023 | 0 | -46.15M | |
Dec 2023 | 560K | -54.51M | -9734.11% |
Mar 2024 | 0 | -62.41M |
Mar 2024 | 0 | -62.41M | |
---|---|---|---|
Sep 2025 | 32.85M | -33.38M | -101.6% |
Oct 2025 | 32.85M | -42.40M | -129.06% |
Dec 2025 | 40.06M | -39.22M | -97.91% |
Analysts Price target
Financials & Ratios estimates
2023-11-06 | -0.6 | -0.54 |
---|---|---|
2024-02-26 | -0.57 | -0.64 |
2024-05-06 | -0.67 | -0.72 |
Jun 2023 | 450756000 | 24.70M | 5.48% |
---|---|---|---|
Sep 2023 | 414179000 | 818.25M | 197.56% |
Dec 2023 | 376048000 | 29.50M | 7.85% |
Mar 2024 | 326645000 | 29.83M | 9.13% |
Jun 2023 | -42.43M | 20.27M | 162.10M |
---|---|---|---|
Sep 2023 | -37.06M | 88.91M | 115K |
Dec 2023 | -41.37M | 30.38M | 597K |
Mar 2024 | -49.72M | 89.28M | 48K |
Day One Biopharmaceuticals alternative data
Sep 2023 | 124 |
---|---|
Oct 2023 | 124 |
Nov 2023 | 124 |
Dec 2023 | 133 |
Jan 2024 | 133 |
Feb 2024 | 133 |
Mar 2024 | 155 |
Apr 2024 | 155 |
May 2024 | 155 |
Jun 2024 | 174 |
Jul 2024 | 174 |
Day One Biopharmaceuticals other data
Period | Buy | Sel |
---|---|---|
Feb 2024 | 0 | 35781 |
Mar 2024 | 0 | 40000 |
Apr 2024 | 0 | 10000 |
May 2024 | 0 | 113357 |
Jun 2024 | 0 | 40000 |
Jul 2024 | 0 | 20000 |
Aug 2024 | 827586 | 18748 |
Sep 2024 | 0 | 30000 |
Oct 2024 | 0 | 500 |
Nov 2024 | 0 | 58027 |
Dec 2024 | 0 | 30000 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | BLACKMAN SAMUEL C. officer: HEAD OF .. | Common Stock | 30,000 | $13.31 | $399,330 | ||
Sale | BENDER JEREMY director, officer: CHIEF EXECUT.. | Common Stock | 10,554 | $13.21 | $139,418 | ||
Sale | BLACKMAN SAMUEL C. officer: HEAD OF .. | Common Stock | 2,206 | $13.21 | $29,141 | ||
Sale | DUBOW ADAM officer: GENERAL COUNSEL | Common Stock | 3,165 | $13.21 | $41,810 | ||
Sale | YORK CHARLES N II officer: COO, CFO AND SECRETARY | Common Stock | 2,602 | $13.21 | $34,372 | ||
Option | BENDER JEREMY director, officer: CHIEF EXECUT.. | Restricted Stock Unit (RSU) | 11,687 | N/A | N/A | ||
Option | BENDER JEREMY director, officer: CHIEF EXECUT.. | Common Stock | 11,687 | N/A | N/A | ||
Option | BENDER JEREMY director, officer: CHIEF EXECUT.. | Common Stock | 4,750 | N/A | N/A | ||
Option | BENDER JEREMY director, officer: CHIEF EXECUT.. | Common Stock | 3,562 | N/A | N/A | ||
Option | BENDER JEREMY director, officer: CHIEF EXECUT.. | Restricted Stock Unit (RSU) | 4,750 | N/A | N/A |
Insider | Compensation |
---|---|
Dr. Jeremy Bender M.B.A., Ph.D. (1972) Chief Executive Officer, Pres & Director | $481,360 |
Dr. Samuel C. Blackman M.D., Ph.D. (1969) Co-Founder & Chief Medical Officer | $477,100 |
Ms. Julie Papanek Grant M.B.A. (1982) Co-Founder & Chair of the Board | $62,910 |
Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301
Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity
Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)
Day One Biopharmaceuticals: Sales Figures In The Crosshairs... And What Else?
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Day One Biopharmaceuticals: NDA Filing Decision Is An Inflection Point To Watch
Diving Into Day One Biopharmaceuticals
Day One Biopharmaceuticals: Strong Potential, Price Drop Opportunity, Some Concerns
-
What's the price of Day One Biopharmaceuticals stock today?
One share of Day One Biopharmaceuticals stock can currently be purchased for approximately $6.81.
-
When is Day One Biopharmaceuticals's next earnings date?
Unfortunately, Day One Biopharmaceuticals's (DAWN) next earnings date is currently unknown.
-
Does Day One Biopharmaceuticals pay dividends?
No, Day One Biopharmaceuticals does not pay dividends.
-
How much money does Day One Biopharmaceuticals make?
Day One Biopharmaceuticals has a market capitalization of 1.27B. Day One Biopharmaceuticals made a loss 188.92M US dollars in net income (profit) last year or -$0.72 on an earnings per share basis.
-
What is Day One Biopharmaceuticals's stock symbol?
Day One Biopharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "DAWN".
-
What is Day One Biopharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Day One Biopharmaceuticals?
Shares of Day One Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Day One Biopharmaceuticals's key executives?
Day One Biopharmaceuticals's management team includes the following people:
- Dr. Jeremy Bender M.B.A., Ph.D. Chief Executive Officer, Pres & Director(age: 53, pay: $481,360)
- Dr. Samuel C. Blackman M.D., Ph.D. Co-Founder & Chief Medical Officer(age: 56, pay: $477,100)
- Ms. Julie Papanek Grant M.B.A. Co-Founder & Chair of the Board(age: 43, pay: $62,910)
-
Is Day One Biopharmaceuticals founder-led company?
Yes, Day One Biopharmaceuticals is a company led by its founders Dr. Samuel C. Blackman M.D., Ph.D. and Ms. Julie Papanek Grant M.B.A..
-
How many employees does Day One Biopharmaceuticals have?
As Jul 2024, Day One Biopharmaceuticals employs 174 workers, which is 12% more then previous quarter.
-
When Day One Biopharmaceuticals went public?
Day One Biopharmaceuticals, Inc. is publicly traded company for more then 4 years since IPO on 27 May 2021.
-
What is Day One Biopharmaceuticals's official website?
The official website for Day One Biopharmaceuticals is dayonebio.com.
-
Where are Day One Biopharmaceuticals's headquarters?
Day One Biopharmaceuticals is headquartered at 395 Oyster Point Boulevard, South San Francisco, CA.
-
How can i contact Day One Biopharmaceuticals?
Day One Biopharmaceuticals's mailing address is 395 Oyster Point Boulevard, South San Francisco, CA and company can be reached via phone at +65 04840899.
Day One Biopharmaceuticals company profile:

Day One Biopharmaceuticals, Inc.
dayonebio.comNASDAQ
174
Biotechnology
Healthcare
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
South San Francisco, CA 94080
CIK: 0001845337
ISIN: US23954D1090
CUSIP: 23954D109